Literature DB >> 31925647

Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review.

Michele Porcu1, Cinzia Solinas2, Cristina Migali3, Angelo Battaglia2, Marina Schena2, Lorenzo Mannelli4, Alfredo Addeo5, Karen Willard-Gallo6, Luca Saba7.   

Abstract

The immunotherapy revolution in cancer treatment involves a variety of specialists, not only oncologists, but also internal medicine physicians, endocrinologists, dermatologists, gastroenterologists, rheumatologists, and radiologists, introducing new scenarios and novel challenges in the diagnosis and management of a number of novel immune-related adverse events. Among these, immune checkpoint inhibitor-induced pancreatic injury has been described (occurring in up to 4% of patients) and has been reported to be responsible for visits to the emergency departments in up to 1.9% of patients treated with immune checkpoint inhibitors. This side effect can be symptomatic or non-symptomatic, and can be associated with the development of long-term damage to the pancreas, requiring the involvement of different specialists, including radiologists and gastroenterologists in the multidisciplinary team that manages these patients. The aim of this narrative review is to provide a summary of the available literature related to immune checkpoint inhibitor-induced pancreatic injury including the epidemiology, the clinical findings, and the management algorithm for diagnosis with a detailed analysis of the differential diagnosis at imaging, and treatment. A more in-depth focus is dedicated to symptomatic acute pancreatitis with its peculiar findings at imaging (ultrasound, computed tomography, and magnetic resonance imaging).

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31925647     DOI: 10.1007/s11523-019-00694-w

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.864


  53 in total

1.  Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury.

Authors:  Yoh Zen; Matthew M Yeh
Journal:  Mod Pathol       Date:  2018-02-05       Impact factor: 7.842

Review 2.  Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?

Authors:  Michele Porcu; Cinzia Solinas; Paolo Garofalo; Evandro de Azambuja; Mario Scartozzi; Karen Willard-Gallo; Matthias Preusser; Luca Saba
Journal:  Crit Rev Oncol Hematol       Date:  2018-04-07       Impact factor: 6.312

Review 3.  Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management.

Authors:  Shilpa Grover; Osama E Rahma; Nikroo Hashemi; Ramona M Lim
Journal:  Am Soc Clin Oncol Educ Book       Date:  2018-05-23

4.  Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Authors:  Jarushka Naidoo; Xuan Wang; Kaitlin M Woo; Tunc Iyriboz; Darragh Halpenny; Jane Cunningham; Jamie E Chaft; Neil H Segal; Margaret K Callahan; Alexander M Lesokhin; Jonathan Rosenberg; Martin H Voss; Charles M Rudin; Hira Rizvi; Xue Hou; Katherine Rodriguez; Melanie Albano; Ruth-Ann Gordon; Charles Leduc; Natasha Rekhtman; Bianca Harris; Alexander M Menzies; Alexander D Guminski; Matteo S Carlino; Benjamin Y Kong; Jedd D Wolchok; Michael A Postow; Georgina V Long; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

Review 5.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

Authors:  Filipe Martins; Latifyan Sofiya; Gerasimos P Sykiotis; Faiza Lamine; Michel Maillard; Montserrat Fraga; Keyvan Shabafrouz; Camillo Ribi; Anne Cairoli; Yan Guex-Crosier; Thierry Kuntzer; Olivier Michielin; Solange Peters; Georges Coukos; Francois Spertini; John A Thompson; Michel Obeid
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

Review 6.  Cancer immunotherapy-associated hypophysitis.

Authors:  Cinzia Solinas; Michele Porcu; Pushpamali De Silva; Marco Musi; Sandrine Aspeslagh; Mario Scartozzi; Karen Willard-Gallo; Stefano Mariotti; Luca Saba
Journal:  Semin Oncol       Date:  2018-10-21       Impact factor: 4.929

Review 7.  Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy.

Authors:  Cinzia Solinas; Michele Porcu; Zuzana Hlavata; Pushpamali De Silva; Marco Puzzoni; Karen Willard-Gallo; Mario Scartozzi; Luca Saba
Journal:  Crit Rev Oncol Hematol       Date:  2017-10-10       Impact factor: 6.312

8.  The Abscopal Effect in the Era of Cancer Immunotherapy: a Spontaneous Synergism Boosting Anti-tumor Immunity?

Authors:  Zuzana Hlavata; Cinzia Solinas; Pushpamali De Silva; Michele Porcu; Luca Saba; Karen Willard-Gallo; Mario Scartozzi
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

Review 9.  Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.

Authors:  Gerlig Widmann; Van Anh Nguyen; Julian Plaickner; Werner Jaschke
Journal:  Curr Radiol Rep       Date:  2017-09-11

Review 10.  Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.

Authors:  Weixun Zhou; Yan Huang; Jinping Lai; Jun Lu; Michael Feely; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2018-05-31
View more
  9 in total

Review 1.  Gastrointestinal adverse events of immunotherapy.

Authors:  Giovanni Cappello; Francesca Molea; Delia Campanella; Francesca Galioto; Filippo Russo; Daniele Regge
Journal:  BJR Open       Date:  2021-10-20

2.  Noninvasive, longitudinal imaging-based analysis of body adipose tissue and water composition in a melanoma mouse model and in immune checkpoint inhibitor-treated metastatic melanoma patients.

Authors:  Wolfgang M Thaiss; Sergios Gatidis; Tina Sartorius; Jürgen Machann; Andreas Peter; Thomas K Eigentler; Konstantin Nikolaou; Bernd J Pichler; Manfred Kneilling
Journal:  Cancer Immunol Immunother       Date:  2020-11-01       Impact factor: 6.968

3.  Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management.

Authors:  Ya Liu; Hao Zhang; Li Zhou; Weichun Li; Le Yang; Wen Li; Kezhou Li; Xubao Liu
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

4.  Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis.

Authors:  Yue Zhang; Yisheng Fang; Jianhua Wu; Genjie Huang; Jianping Bin; Yulin Liao; Min Shi; Wangjun Liao; Na Huang
Journal:  Front Pharmacol       Date:  2022-04-01       Impact factor: 5.988

5.  Immune-related pancreatitis due to anti-PD-L1 therapy in a patient with non-small cell lung cancer: A case report.

Authors:  Julie Malet; Boutheina Melki; Stéphane Chouabe; Gaëtan Deslée
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

Review 6.  Synergetic Thermal Therapy for Cancer: State-of-the-Art and the Future.

Authors:  Qizheng Dai; Bo Cao; Shiqing Zhao; Aili Zhang
Journal:  Bioengineering (Basel)       Date:  2022-09-15

Review 7.  Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis.

Authors:  Tian Zhang; Yi Wang; Chunhui Shi; Xiaochun Liu; Shangbin Lv; Xin Wang; Weihong Li
Journal:  Front Pharmacol       Date:  2022-09-05       Impact factor: 5.988

8.  The diagnosis of immune-related pancreatitis disguised as multifocal lesions on MRI by endoscopic ultrasound-guided fine-needle biopsy: A case report.

Authors:  Wen Shi; Bei Tan; Yuan Li; Liang Zhu; Yunlu Feng; Qingwei Jiang; Jiaming Qian
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

9.  Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events.

Authors:  Bei Tan; Min-Jiang Chen; Qi Guo; Hao Tang; Yue Li; Xin-Miao Jia; Yan Xu; Liang Zhu; Meng-Zhao Wang; Jia-Ming Qian
Journal:  Thorac Cancer       Date:  2021-05-04       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.